Hikal Q1 Results: Earnings Call Scheduled for August 6
Hikal Limited is hosting an earnings call on August 06, 2026, to discuss Q1FY27 results. The event, compliant with SEBI Regulation 30, features senior executives including Sameer Hiremath and Kuldeep Jain. Investors can dial in via universal or international numbers to gain insights into the company's financial and operational performance for the quarter ended June 30, 2026.

*this image is generated using AI for illustrative purposes only.
Hikal Limited will host an earnings group conference call on Thursday, August 06, 2026, at 5:00 PM IST to discuss its financial and operational performance for the quarter ended June 30, 2026. The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, providing investors with a direct channel to management for insights into Q1FY27 results.
The call aims to address investor queries regarding the company’s recent quarterly outcomes. Hikal Limited notified both the Bombay Stock Exchange and the National Stock Exchange of India Limited regarding the event. The company secretary, Rajasekhar Reddy Chintakindi, signed the intimation dated July 30, 2026, ensuring compliance with regulatory disclosure norms.
Conference Call Participants
Senior leadership from Hikal Limited will participate in the discussion to provide detailed commentary on the quarter’s performance. The key participants include:
| Name | Designation |
|---|---|
| Sameer Hiremath | Vice Chairman and Managing Director |
| Anish Swadi | Senior President, Business Transformation and Animal Health |
| Kuldeep Jain | Chief Financial Officer |
| Manoj Mehrotra | President, Pharmaceuticals Business |
Dial-In Details
Investors and analysts can join the call using the provided dial-in numbers. Strategic Growth Advisors Pvt. Ltd. is facilitating the registration process.
- Universal Access: +91 22 6280 1309, +91 22 7115 8210
- Hong Kong: 800964448
- Singapore: 8001012045
- UK: 08081011573
- USA: 18667462133
For RSVP inquiries, investors may contact Mr. Jigar Kavaiya at jigar.kavaiya@sgapl.net or Ms. Ami Parekh at ami.parekh@sgapl.net .
What This Means for Investors
The conference call serves as a critical platform for stakeholders to understand the drivers behind Hikal Limited’s Q1FY27 financial results. With participation from the CFO and business heads, the session is expected to cover segment-wise performance, particularly in Pharmaceuticals and Animal Health, as well as broader business transformation initiatives. Investors should note that no specific financial figures were disclosed in this announcement; all material data will be presented during the live discussion.
Historical Stock Returns for Hikal
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.98% | +1.56% | +0.96% | +13.60% | -33.12% | -58.64% |
How will Hikal's Q1FY27 performance in the Animal Health segment influence its strategic prioritization between pharmaceuticals and agribusiness in the coming fiscal year?
What specific milestones or ROI metrics can investors expect from the business transformation initiatives led by Anish Swadi during the upcoming quarters?
Given the current global regulatory landscape for APIs, how does management plan to mitigate supply chain risks and maintain margin stability for FY27?


































